Pharmacokinetics and Metabolism of Cyclopentenyl Cytosine in Nonhuman Primates

Cancer Research

Volumn 50, Issue 24, 1990, Pages 7915-7919

  Blaney, Susan M ^a,b   Balis, Frank M ^b   Heideman, Richard L ^b   McCully, Cynthia ^b   Murphy, Robert F ^b   Poplack, David G ^b   Hegedus, Lajos ^b   Kelley, James A ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; CYTARABINE;

ANIMAL EXPERIMENT; ARTICLE; CEREBROSPINAL FLUID LEVEL; DRUG BLOOD LEVEL; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; COMPARATIVE STUDY; CYTIDINE; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MICE; MOLECULAR STRUCTURE; RATS; SPECIES SPECIFICITY;

EID: 0025686123     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lim, M.-L., Moyer, J. D., Cysk, R. L., and Marquez, V. D. Cyclopentenylur-idine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase. J. Med. Chem., 27: 1536–1538, 1984.
2. Driscoll, J. S., Marquez, V. E., and Treanor, S. P. Cyclopentenyl cytosine. A neplanocin analogue with preclinical antitumor and antiviral activity. Proc. Am. Assoc. Cancer Res., 28: 328, 1987.
3. Marquez, V. E., Lim, M.-I., Treanor, S. P., Plowman, J., Priest, M. A., Markovac, A., Khan, M. S., Kaskar, B., and Driscoll, J. S. Cyclopentenylcytosine: a carbocyclic nucleoside with antitumor and antiviral properties. J. Med. Chem., 31: 1687–1694, 1988.
4. Moyer, J. D., Malinowski, N. M., Treanor, S. P., and Marquez, V. E. Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice. Cancer Res., 46: 3325–3329, 1986.
5. Glazer, R. I., Knode, M. C., Lim, M.-I., and Marquez, V. E. Cyclopentenyl cytidine analogue: an inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells. Biochem. Pharmacol., 34: 2535–2539, 1985.
6. Glazer, R. I., Cohen, M. B., Hartman, K. D., Knode, M. C., Lim, M.-I., and Marquez, V. E. Induction of differentiation in the human promyelocyte leukemia cell line HL-60 by the cyclopentenyl analogue of cytidine. Biochem. Pharmacol., 35: 1841–1848, 1986.
7. Kang, G. J., Cooney, D. A., Moyer, J. D., Kelley, J. A., Kim, H.-Y., Marquez, V. E., and Johns, D. G. Cyclopentenylcytosine triphosphate: formation and inhibition of CTP synthetase. J. Biol. Chem., 264: 713–718, 1989.
8. Zaharko, D. S., Kelley, J. A., Tomaszewski, J. E., Hegedus, L., and Hartman, N. R. Cyclopentenyl cytosine: intraspecies predictions based on rodent plasma and renal kinetics. Invest. New Drugs, in press, 1990.
9. Camiener, G. W., and Smith, C. G. Studies of the enzymatic deamination of cytosine arabinoside-I: Enzyme distribution and species specificity. Biochem. Pharmacol. 14: 1405–1416, 1965.
10. Guide for the Care and Use of Laboratory Animals. DHEW Publication (NIH) 85-23, revised 1988.
11. Wood, J. H., Poplack, D. G., Bleyer, W. A., and Ommaya, A. K. Primate model for the chronic study of intraventricularly or intrathecally administered drug and intracranial pressure. Science (Washington DC), 195: 499–500, 1977.
12. Zimm, S., Collins, J. M., Miser, J., Chatterji, D., and Poplack, D. Cytosine arabinoside cerebrospinal fluid kinetics. Clin. Pharmacol. Ther., 35: 826–830, 1984.
13. Knott, G. D. MLAB: a mathematical modeling tool. Comput. Programs Biomed., 10: 271–280, 1979.
14. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's information criterion (AIQ in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165–175, 1978.
15. Gibaldi, M., and Perrier, D. Estimation of areas. In: Pharmacokinetics, Ed. 2, pp. 445–449. New York: Marcel Dekker, Inc., 1982.
16. Perrier, D., and Mayersohn, M. Noncompartmental determination of steady state volume of distribution for any mode of administration. J. Pharm Sci., 77: 372–373, 1982.
17. Poplack, D. G., Bleyer, W. A., Wood, J. H., Kostolich, M., Savitch, J. L., and Ommaya, A. K. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res., 37: 1982–1985, 1977.
18. Heideman, R. L., Balis, F. M., McCully, C., and Poplack, D. G. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res., 48: 4294–4298, 1988.
19. Grieshaber, C. K., and Marsoni, S. Relations of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep., 70: 65–72, 1986.
20. Donehower, R. C., Karp, J. E., and Burke, P. J. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat. Rep., 70: 1059–1065, 1986.
21. Kelley, J. A., Litterst, C. L., Roth, J. S., Vistica, D. T., Poplack, D. G., Cooney, D. A., Nadkarni, M., Balis, F. M., Broder, S. B., and Johns, D. G. The disposition and metabolism of 2′, 3′-dideoxycytidine, an in vitro inhibitor of HTLV-III infectivity, in mice and monkeys. Drug Metab. Dispos. 15: 595–601, 1987.
22. Klecker, R. W., Collins, J. M., Yarchoan, R. C., Thomas, R., McAtee, N., Broder, S., and Myers, C. E. Pharmacokinetics of 2′, 3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol., 28: 837–842, 1988.
23. Collins, J. M., Zaharko, D. S., Dedrick, R. L., and Chabner, B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep., 70: 73–80, 1986.
24. Collins, J. M., Klecker, R. W., Kelley, J. A., Roth, J. S., McCully, C. L., Balis, F. M., and Poplack, D. G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther., 245: 466–470, 1988.
25. Grem, J. L., and Allegra, C. J. Mechanism of action of cyclopentenyl cytosine and biochemical modulation of cytosine arabinoside. Proc. Am. Assoc. Cancer Res., 31: 421, 1990.